PCKS9s Seen Driving Down LDL-C in Diabetes

A subgroup analysis of the VASALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/pcks9s-seen-driving-down-ldl-c-diabetes-2026a10009jb?src=rss

Author :

Publish date : 2026-03-29 18:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

PCKS9s Seen Driving Down LDL-C in Diabetes

Melasma: A New Era of Topical Treatment Options Galore

Resistant Dermatomyositis Improves Quickly, Significantly With Combination Drug

Related Posts

Impella Flops for Acute Coronary Syndrome Patients Not in Shock

Pregnancy-Associated SCAD Is Often More Severe Yet Still Conservatively Managed

‘Who Would Do Something So Stupid?’: What We Heard This Week

Lower Really Is Better for Secondary Prevention Cholesterol Targets

False-Negative CAC Findings That Equal Zero Cluster in Certain Groups, Study Finds

High Dx Yield Supports Workup for INOCA

Impella Flops for Acute Coronary Syndrome Patients Not in Shock

Pregnancy-Associated SCAD Is Often More Severe Yet Still Conservatively Managed

‘Who Would Do Something So Stupid?’: What We Heard This Week

Lower Really Is Better for Secondary Prevention Cholesterol Targets

False-Negative CAC Findings That Equal Zero Cluster in Certain Groups, Study Finds

High Dx Yield Supports Workup for INOCA

Resistant Dermatomyositis Improves Quickly, Significantly With Combination Drug

PCKS9s Seen Driving Down LDL-C in Diabetes

Categories

Archives